The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B

被引:3
|
作者
Shindo, M
Hamada, K
Koya, S
Sokawa, Y
Okuno, T
机构
[1] Akashi Municipal Hosp, Dept Internal Med, Div Liver Dis, Kobe, Hyogo 673, Japan
[2] Kyoto Inst Technol, Dept Mol Biol, Kyoto 606, Japan
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 1999年 / 94卷 / 08期
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: We aimed to determine the clinical significance of mutations in core promoter and precore regions in chronic hepatitis B. We investigated changes in these mutations during the natural course and interferon therapy in patients with chronic hepatitis B. METHODS: A total of 93 patients with hepatitis B virus surface antigen were divided into four groups according to hepatitis B e antigen (HBeAg)/anti-HBe status and serum aminotransferase levels. Group I (n = 16) comprised HBeAg-positive patients with normal aminotransferase levels, group n (n = 31) HBeAg-positive patients with elevated aminotransferase levels, group III (n = 30) anti-HBe-positive patients with normal aminotransferase levels, and group IV (n = 16) anti-HBe-positive patients with elevated aminotransferase levels. All patients of group II and seven of group IV were treated with interferon. Three serial serum samples per untreated patient and eight samples per treated patient were tested for HBV DNA levels and core promoter and precore mutations by polymerase chain reaction combined with restriction fragment length polymorphism, and some were cloned and sequenced. RESULTS: Core promoter mutation was found in 38% of group I, 74% of group II, 97% of group III, and 100% of group IV. Precore mutation was found in 6% of group I, 90% of group II, and 100% of groups III and IV. The HBV DNA levels were significantly higher in groups I, II, IV, and III, in that order. Serial determination of these two mutations and viral levels showed that the core promoter mutation appeared to occur first, followed by a completion of the precore mutation along with a decrease in viral levels in patients who seroconverted to anti-HBe after interferon therapy. Interferon therapy suppressed both precore wild- and mutated-type viral levels equally. However, it did not induce any specific mutations. CONCLUSIONS: Core promoter mutation appeared to develop or complete first, followed by completion of the precore mutation, and the virus with these two mutations seemed to be the form to persist in the natural course of chronic hepatitis B. The clinical significance of these mutations appeared to be profoundly associated with the viral levels. (Am J Gastroenterol 1999;94:2237-2245. (C) 1999 by Am. Cell. of Gastroenterology).
引用
收藏
页码:2237 / 2245
页数:9
相关论文
共 50 条
  • [1] Clinical significance of core promoter and precore mutations in chronic hepatitis B
    Martinot-Peignoux, Michelle
    Lapalus, Martine
    Laouenan, Cedric
    Cardoso, Ana Carolina
    Carvalho-Filho, Roberto J.
    El Ray, Ahmed
    Gosset, Simon
    Boyer, Nathalie
    Asselah, Tarik
    Marcellin, Patrick
    [J]. HEPATOLOGY, 2013, 58 : 729A - 729A
  • [2] CLINICAL SIGNIFICANCE OF PRECORE AND CORE PROMOTER MUTATIONS IN KOREAN CHRONIC HEPATITIS B PATIENTS
    Yim, S. Y.
    Um, S. H.
    Kim, J. D.
    Jung, J. Y.
    Kim, C. H.
    Seo, Y. S.
    Yim, H. J.
    Keum, B.
    Jeen, Y. T.
    Lee, H. S.
    Chun, H. J.
    Kim, C. D.
    Ryu, H. S.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S194 - S194
  • [3] Clinical significance of basal core promoter and precore mutations in chronic hepatitis B
    Ozgenc, O.
    Ozacar, T.
    Erensoy, S.
    Inan, N.
    Ari, A.
    Kuruuzum, Z.
    Bilgic, A.
    [J]. HEPATO-GASTROENTEROLOGY, 2007, 54 (80) : 2319 - 2323
  • [4] Changes in core promotor and precore mutations in the natural course of chronic hepatitis B and on interferon therapy.
    Shindo, M
    Hamada, S
    Koya, S
    Arai, K
    Sokawa, Y
    Okuno, T
    [J]. HEPATOLOGY, 1996, 24 (04) : 609 - 609
  • [5] Evolution of the core promoter, precore and core gene mutations of hepatitis B virus during lamivudine therapy in patients with chronic hepatitis B
    Kim, SS
    Jin, HY
    Kwon, KA
    Chung, MG
    Park, DK
    Kim, YS
    Kwon, SY
    Kim, YK
    Choi, DJ
    Kim, JH
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A710 - A710
  • [6] Clinical Significance of Hepatitis B Virus Precore and Core Promoter Variants in Korean Patients With Chronic Hepatitis B
    Yim, Sun Young
    Um, Soon Ho
    Jung, Jin Young
    Kim, Tae Hyung
    Kim, Jin Dong
    Keum, Bora
    Seo, Yeon Seok
    Yim, Hyung Joon
    Jeen, Yoon Tae
    Lee, Hong Sik
    Chun, Hoon Jai
    Kim, Chang Duck
    Ryu, Ho Sang
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (01) : 61 - 68
  • [7] High rate of core promoter and precore mutations in patients with chronic hepatitis B
    Baqai, Sumbella F.
    Proudfoot, James
    Yi, Debbie H.
    Mangahas, Michael
    Gish, Robert G.
    [J]. HEPATOLOGY INTERNATIONAL, 2015, 9 (02) : 209 - 217
  • [8] Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia
    Juniastuti
    Utsumi, Takako
    Aksono, Eduardus Bimo
    Yano, Yoshihiko
    Soetjipto
    Hayashi, Yoshitake
    Hotta, Hak
    Rantam, Fedik Abdul
    Kusumobroto, Hernomo Ontoseno
    Lusida, Maria Inge
    [J]. BIOMEDICAL REPORTS, 2013, 1 (04) : 522 - 528
  • [9] High rate of core promoter and precore mutations in patients with chronic hepatitis B
    Sumbella F. Baqai
    James Proudfoot
    Debbie H. Yi
    Michael Mangahas
    Robert G. Gish
    [J]. Hepatology International, 2015, 9 : 209 - 217
  • [10] Dynamic changes of precore and basal core promoter mutations in HBeAg-positive chronic hepatitis B patients receiving interferon therapy
    Yang, Hung-Chih
    Chen, Chi-Ling
    Shen, Yueh-Chi
    Peng, Cheng-Yuan
    Liu, Chun-Jen
    Tseng, Tai-Chung
    Su, Tung-Hung
    Chuang, Wan-Long
    Yu, Ming-Lung
    Dai, Chia-Yen
    Liu, Chen-Hua
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. HEPATOLOGY, 2012, 56 : 358A - 358A